Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
Targeting the immune system has emerged as an effective therapeutic strategy for the treatment of various tumor types, including Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-small-Cell Lung Cancer (NSCLC), and checkpoint inhibitors have shown to improve patient survival in these tumor types...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.714550/full |
id |
doaj-e2613e8de59843d685eb5e3e8880fef6 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cristina Saiz-Ladera Mariona Baliu-Piqué Francisco J. Cimas Aránzazu Manzano Vanesa García-Barberán Santiago Cabezas Camarero Gonzalo Fernández Hinojal Atanasio Pandiella Balázs Győrffy Balázs Győrffy Balázs Győrffy David Stewart Juan J. Cruz-Hernández Pedro Pérez-Segura Alberto Ocana Alberto Ocana |
spellingShingle |
Cristina Saiz-Ladera Mariona Baliu-Piqué Francisco J. Cimas Aránzazu Manzano Vanesa García-Barberán Santiago Cabezas Camarero Gonzalo Fernández Hinojal Atanasio Pandiella Balázs Győrffy Balázs Győrffy Balázs Győrffy David Stewart Juan J. Cruz-Hernández Pedro Pérez-Segura Alberto Ocana Alberto Ocana Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer Frontiers in Oncology head and neck squamous cell carcinoma (HNSCC) human papillomavirus transcriptome signature immune gene signatures cervical squamous cell carcinoma (CSCC) |
author_facet |
Cristina Saiz-Ladera Mariona Baliu-Piqué Francisco J. Cimas Aránzazu Manzano Vanesa García-Barberán Santiago Cabezas Camarero Gonzalo Fernández Hinojal Atanasio Pandiella Balázs Győrffy Balázs Győrffy Balázs Győrffy David Stewart Juan J. Cruz-Hernández Pedro Pérez-Segura Alberto Ocana Alberto Ocana |
author_sort |
Cristina Saiz-Ladera |
title |
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer |
title_short |
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer |
title_full |
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer |
title_fullStr |
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer |
title_full_unstemmed |
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer |
title_sort |
transcriptomic correlates of immunologic activation in head and neck and cervical cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-10-01 |
description |
Targeting the immune system has emerged as an effective therapeutic strategy for the treatment of various tumor types, including Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-small-Cell Lung Cancer (NSCLC), and checkpoint inhibitors have shown to improve patient survival in these tumor types. Unfortunately, not all cancers respond to these agents, making it necessary to identify responsive tumors. Several biomarkers of response have been described and clinically tested. As of yet what seems to be clear is that a pre-activation state of the immune system is necessary for these agents to be efficient. In this study, using established transcriptomic signatures, we identified a group of gene combination associated with favorable outcome in HNSCC linked to a higher presence of immune effector cells. CD2, CD3D, CD3E, and CXCR6 combined gene expression is associated with improved outcome of HNSCC patients and an increase of infiltrating immune effector cells. This new signature also identifies a subset of cervical squamous cell carcinoma (CSCC) patients with favorable prognosis, who show an increased presence of immune effector cells in the tumor, which outcome shows similarities with the HP-positive HNSCC cohort of patients. In addition, CD2, CD3D, CD3E, and CXCR6 signature is able to predict the best favorable prognosis in terms of overall survival of CSSC patients. Of note, these findings were not reproduced in other squamous cell carcinomas like esophageal SCC or lung SCC. Prospective confirmatory studies should be employed to validate these findings. |
topic |
head and neck squamous cell carcinoma (HNSCC) human papillomavirus transcriptome signature immune gene signatures cervical squamous cell carcinoma (CSCC) |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.714550/full |
work_keys_str_mv |
AT cristinasaizladera transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT marionabaliupique transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT franciscojcimas transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT aranzazumanzano transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT vanesagarciabarberan transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT santiagocabezascamarero transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT gonzalofernandezhinojal transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT atanasiopandiella transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT balazsgyorffy transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT balazsgyorffy transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT balazsgyorffy transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT davidstewart transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT juanjcruzhernandez transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT pedroperezsegura transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT albertoocana transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer AT albertoocana transcriptomiccorrelatesofimmunologicactivationinheadandneckandcervicalcancer |
_version_ |
1716840802557100032 |
spelling |
doaj-e2613e8de59843d685eb5e3e8880fef62021-10-06T12:32:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.714550714550Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical CancerCristina Saiz-Ladera0Mariona Baliu-Piqué1Francisco J. Cimas2Aránzazu Manzano3Vanesa García-Barberán4Santiago Cabezas Camarero5Gonzalo Fernández Hinojal6Atanasio Pandiella7Balázs Győrffy8Balázs Győrffy9Balázs Győrffy10David Stewart11Juan J. Cruz-Hernández12Pedro Pérez-Segura13Alberto Ocana14Alberto Ocana15Experimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainTranslational Oncology Laboratory, Centro Regional de Investigaciones Biomedicas, Castilla‐La Mancha University (CRIB‐UCLM), Albacete, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainInstituto de Biología Molecular y Celular del Cáncer and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Centro Superior de Investigaciones Científicas (CSIC), Salamanca, SpainDepartment of Bioinformatics, Faculty of Medicine, Semmelweis University, Budapest, Hungary2nd Department of Pediatrics, Faculty of Medicine, Semmelweis University, Budapest, HungaryInstitute of Enzymology, Research Centre of Nature Sciences, Budapest, HungaryOttawa University Hospital, University of Ottawa, Ottawa, ON, CanadaInstituto de Biología Molecular y Celular del Cáncer and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Centro Superior de Investigaciones Científicas (CSIC), Salamanca, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainExperimental Therapeutics Unit, Medical Oncology Department, Hospital Clínico Universitario San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC), Madrid, SpainTranslational Oncology Laboratory, Centro Regional de Investigaciones Biomedicas, Castilla‐La Mancha University (CRIB‐UCLM), Albacete, SpainTargeting the immune system has emerged as an effective therapeutic strategy for the treatment of various tumor types, including Head and Neck Squamous Cell Carcinoma (HNSCC) and Non-small-Cell Lung Cancer (NSCLC), and checkpoint inhibitors have shown to improve patient survival in these tumor types. Unfortunately, not all cancers respond to these agents, making it necessary to identify responsive tumors. Several biomarkers of response have been described and clinically tested. As of yet what seems to be clear is that a pre-activation state of the immune system is necessary for these agents to be efficient. In this study, using established transcriptomic signatures, we identified a group of gene combination associated with favorable outcome in HNSCC linked to a higher presence of immune effector cells. CD2, CD3D, CD3E, and CXCR6 combined gene expression is associated with improved outcome of HNSCC patients and an increase of infiltrating immune effector cells. This new signature also identifies a subset of cervical squamous cell carcinoma (CSCC) patients with favorable prognosis, who show an increased presence of immune effector cells in the tumor, which outcome shows similarities with the HP-positive HNSCC cohort of patients. In addition, CD2, CD3D, CD3E, and CXCR6 signature is able to predict the best favorable prognosis in terms of overall survival of CSSC patients. Of note, these findings were not reproduced in other squamous cell carcinomas like esophageal SCC or lung SCC. Prospective confirmatory studies should be employed to validate these findings.https://www.frontiersin.org/articles/10.3389/fonc.2021.714550/fullhead and neck squamous cell carcinoma (HNSCC)human papillomavirustranscriptome signatureimmune gene signaturescervical squamous cell carcinoma (CSCC) |